Outcome of donor-derived TAA-T cell therapy in patients with high-risk or relapsed acute leukemia post allogeneic BMT

Patients with hematologic malignancies relapsing after allogeneic blood or marrow transplantation (BMT) have limited response to conventional salvage therapies, with an expected 1-year overall survival (OS) of <20%. We evaluated the safety and clinical outcomes following administration of a novel...

Descripción completa

Detalles Bibliográficos
Autores principales: Kinoshita, Hannah, Cooke, Kenneth R., Grant, Melanie, Stanojevic, Maja, Cruz, C. Russell, Keller, Michael, Fortiz, Maria Fernanda, Hoq, Fahmida, Lang, Haili, Barrett, A. John, Liang, Hua, Tanna, Jay, Zhang, Nan, Shibli, Abeer, Datar, Anushree, Fulton, Kenneth, Kukadiya, Divyesh, Zhang, Anqing, Williams, Kirsten M., Dave, Hema, Dome, Jeffrey S., Jacobsohn, David, Hanley, Patrick J., Jones, Richard J., Bollard, Catherine M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology 2022
Materias:
Clinical Trials and Observations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9043933/
https://www.ncbi.nlm.nih.gov/pubmed/35244681
http://dx.doi.org/10.1182/bloodadvances.2021006831

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9043933/
https://www.ncbi.nlm.nih.gov/pubmed/35244681
http://dx.doi.org/10.1182/bloodadvances.2021006831

Ejemplares similares